StockData
Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Inc. (APVO) KPIs and segments

APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.55−0.05 (-7.66%)

Close on Nov 16, 2026Market cap $988.56KP/E –Yield –

KPIs & segments

Operating metrics and segments that drive Aptevo Therapeutics's business

Aptevo Therapeutics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Add to chartMetric
Q4 2018
Q3 2018
Q2 2018
Q4 2017
Q3 2017
Q2 2017
Earlier reporting (last reported 2019)2

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics
  • Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).

Data updated 2020-03-25.

See a number that looks wrong?